{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:23:42Z","timestamp":1789503822874,"version":"build-2803163510"},"reference-count":173,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Spanish Ministry of Science and Innovation","doi-asserted-by":"publisher","award":["PID2021-128891OB-I00"],"award-info":[{"award-number":["PID2021-128891OB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Spanish Ministry of Science and Innovation","doi-asserted-by":"publisher","award":["PLEC2021- 007664"],"award-info":[{"award-number":["PLEC2021- 007664"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Spanish Ministry of Science and Innovation","doi-asserted-by":"publisher","award":["SEC\/FEC-INV-TRL 20\/015"],"award-info":[{"award-number":["SEC\/FEC-INV-TRL 20\/015"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Spanish Ministry of Science and Innovation","doi-asserted-by":"publisher","award":["PID2021-128891OB-I00"],"award-info":[{"award-number":["PID2021-128891OB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Spanish Ministry of Science and Innovation","doi-asserted-by":"publisher","award":["PLEC2021- 007664"],"award-info":[{"award-number":["PLEC2021- 007664"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Spanish Ministry of Science and Innovation","doi-asserted-by":"publisher","award":["SEC\/FEC-INV-TRL 20\/015"],"award-info":[{"award-number":["SEC\/FEC-INV-TRL 20\/015"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Spanish Society of Cardiology","award":["PID2021-128891OB-I00"],"award-info":[{"award-number":["PID2021-128891OB-I00"]}]},{"name":"Spanish Society of Cardiology","award":["PLEC2021- 007664"],"award-info":[{"award-number":["PLEC2021- 007664"]}]},{"name":"Spanish Society of Cardiology","award":["SEC\/FEC-INV-TRL 20\/015"],"award-info":[{"award-number":["SEC\/FEC-INV-TRL 20\/015"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCDD"],"abstract":"<jats:p>Ischemic cardiovascular diseases have a high incidence and high mortality worldwide. Therapeutic advances in the last decades have reduced cardiovascular mortality, with antithrombotic therapy being the cornerstone of medical treatment. Yet, currently used antithrombotic agents carry an inherent risk of bleeding associated with adverse cardiovascular outcomes and mortality. Advances in understanding the pathophysiology of thrombus formation have led to the discovery of new targets and the development of new anticoagulants and antiplatelet agents aimed at preventing thrombus stabilization and growth while preserving hemostasis. In the following review, we will comment on the key limitation of the currently used antithrombotic regimes in ischemic heart disease and ischemic stroke and provide an in-depth and state-of-the-art overview of the emerging anticoagulant and antiplatelet agents in the pipeline with the potential to improve clinical outcomes.<\/jats:p>","DOI":"10.3390\/jcdd9110397","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T03:27:44Z","timestamp":1668655664000},"page":"397","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Novel Antithrombotic Agents in Ischemic Cardiovascular Disease: Progress in the Search for the Optimal Treatment"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8670-4898","authenticated-orcid":false,"given":"Ignacio","family":"Barriuso","sequence":"first","affiliation":[{"name":"Hospital Universitario Arnau de Vilanova, Institut de Recerca Biom\u00e8dica de Lleida, 25198 Lleida, Spain"},{"name":"Institut de Recerca, Hospital Santa Creu i Sant Pau, IIB Sant Pau, 08025 Barcelona, Spain"},{"name":"Department of Medicine, Autonomous University of Barcelona, 08193 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Worner","sequence":"additional","affiliation":[{"name":"Hospital Universitario Arnau de Vilanova, Institut de Recerca Biom\u00e8dica de Lleida, 25198 Lleida, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Vilahur","sequence":"additional","affiliation":[{"name":"Institut de Recerca, Hospital Santa Creu i Sant Pau, IIB Sant Pau, 08025 Barcelona, Spain"},{"name":"Centro de Investigaciones Biom\u00e9dicas En Red de enfermedades CardioVasculares (CiberCV), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"key":"ref_1","unstructured":"(2022, September 24). Cardiovascular Diseases (CVDs) [Internet]. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds)."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa1406656","article-title":"Demographic and Epidemiologic Drivers of Global Cardiovascular Mortality","volume":"372","author":"Roth","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_3","unstructured":"Global Burden of Disease Collaborative Network (2019). Global Burden of Disease Study 2019 (GBD 2019) Results, Institute for Health Metrics and Evaluation (IHME). Available online: http:\/\/ghdx.healthdata.org\/gbd-results-tool."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1093\/eurheartj\/sut003","article-title":"Perspectives: The burden of cardiovascular risk factors and coronary heart disease in Europe and worldwide","volume":"16","author":"Vilahur","year":"2014","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1160\/THS10-11-0717","article-title":"Update on lipids, inflammation and atherothrombosis","volume":"105","author":"Badimon","year":"2011","journal-title":"Thromb. Haemost."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.jacc.2017.08.037","article-title":"Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis","volume":"70","author":"Patrono","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000107377","article-title":"Platelets, arterial thrombosis and cerebral ischemia","volume":"24","author":"Badimon","year":"2007","journal-title":"Cerebrovasc. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1177\/2048872612441582","article-title":"Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease","volume":"1","author":"Badimon","year":"2012","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"M26","DOI":"10.1093\/eurheartj\/suaa165","article-title":"Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial disease","volume":"22","author":"Parker","year":"2020","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_11","first-page":"496","article-title":"Epidemiology of atrial fibrillation-related ischemic stroke and its association with DOAC uptake in Spain: First national population-based study 2005 to 2018","volume":"75","author":"Cabeza","year":"2022","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1161\/STROKEAHA.117.018773","article-title":"Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients with Atrial Fibrillation","volume":"48","author":"Cha","year":"2017","journal-title":"Stroke"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/1076029616675970","article-title":"Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants","volume":"23","author":"Dhakal","year":"2017","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/21548331.2019.1643728","article-title":"Reversal agents for direct oral anticoagulants: Considerations for hospital physicians and intensivists","volume":"47","author":"Desai","year":"2019","journal-title":"Hosp. Pract."},{"key":"ref_15","first-page":"67","article-title":"Strategies of neutralization of the direct oral anticoagulants effect: Review of the literature","volume":"77","author":"Jourdi","year":"2019","journal-title":"Ann. Biol. Clin."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood.2020007116","article-title":"Ciraparantag, an anticoagulant reversal drug: Mechanism of action, pharmacokinetics, and reversal of anticoagulants","volume":"137","author":"Ansell","year":"2021","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1056\/NEJMc1411800","article-title":"Use of PER977 to reverse the anticoagulant effect of edoxaban","volume":"371","author":"Ansell","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/jth.12601","article-title":"\u03b3T-S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo","volume":"12","author":"Sheffield","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ijbiomac.2021.06.058","article-title":"Induced forms of \u03b12-macroglobulin neutralize heparin and direct oral anticoagulant effects","volume":"184","author":"Jourdi","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(20)32439-9","article-title":"Direct oral anticoagulants: Evidence and unresolved issues","volume":"396","author":"Chan","year":"2020","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/01.CIR.90.1.61","article-title":"Persistent activation of coagulation mechanism in unstable angina and myocardial infarction","volume":"90","author":"Merlini","year":"1994","journal-title":"Circulation"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-143-4-200508160-00005","article-title":"Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: Meta-analysis with estimates of risk and benefit","volume":"143","author":"Rothberg","year":"2005","journal-title":"Ann. Intern. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(03)14287-0","article-title":"Oral ximelagatran for secondary prophylaxis after myocardial infarction: The ESTEEM randomised controlled trial","volume":"362","author":"Wallentin","year":"2003","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.hoc.2016.05.007","article-title":"The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy","volume":"30","author":"Wheeler","year":"2016","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/rth2.12235","article-title":"Factor XII\u2014What\u2019s important but not commonly thought about","volume":"3","author":"Schmaier","year":"2019","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.1038\/s41467-021-25888-7","article-title":"Identification of the factor XII contact activation site enables sensitive coagulation diagnostics","volume":"12","author":"Heestermans","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/MOH.0000000000000603","article-title":"The rebirth of the contact pathway: A new therapeutic target","volume":"27","author":"Srivastava","year":"2020","journal-title":"Curr. Opin. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1080\/13543776.2021.1945580","article-title":"Factor XII(a) inhibitors: A review of the patent literature","volume":"31","author":"Kalinin","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/jth.15126","article-title":"New anticoagulants: Moving beyond the direct oral anticoagulants","volume":"19","author":"Fredenburgh","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(21)02225-X","article-title":"Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"399","author":"Craig","year":"2022","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/cts.13180","article-title":"A phase I, first-in-human, randomized dose-escalation study of anti-activated factor XII monoclonal antibody garadacimab","volume":"15","author":"McKenzie","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"222ra17","DOI":"10.1126\/scitranslmed.3006804","article-title":"A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk","volume":"6","author":"Larsson","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_37","first-page":"247","article-title":"The factor XIIa blocking antibody 3F7: A safe anticoagulant with anti-inflammatory activities","volume":"3","author":"Worm","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood-2013-04-499111","article-title":"Factor XII inhibition reduces thrombus formation in a primate thrombosis model","volume":"123","author":"Matafonov","year":"2014","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/rth2.12309","article-title":"Antibody inhibition of contact factor XII reduces platelet deposition in a model of extracorporeal membrane oxygenator perfusion in nonhuman primates","volume":"4","author":"Wallisch","year":"2020","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2019.08.1028","article-title":"Anticoagulation with an Inhibitor of Factors XIa and XIIa During Cardiopulmonary Bypass","volume":"74","author":"Pireaux","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/jth.15130","article-title":"Dual inhibition of factor XIIa and factor XIa as a therapeutic approach for safe thromboprotection","volume":"19","author":"Demoulin","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1084\/jem.20091007","article-title":"Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis","volume":"206","author":"Decrem","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood-2013-12-540872","article-title":"Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits","volume":"123","author":"Yau","year":"2014","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.thromres.2020.08.040","article-title":"Knockdown of liver-derived factor XII by GalNAc-siRNA ALN-F12 prevents thrombosis in mice without impacting hemostatic function","volume":"196","author":"Liu","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/bjh.13990","article-title":"FXIIa inhibitor rHA-Infestin-4: Safe thromboprotection in experimental venous, arterial and foreign surface-induced thrombosis","volume":"173","author":"May","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Krupka, J., May, F., Weimer, T., Pragst, I., Kleinschnitz, C., Stoll, G., Panousis, C., Dickneite, G., and Nolte, M.W. (2016). The Coagulation Factor XIIa Inhibitor rHA-Infestin-4 Improves Outcome after Cerebral Ischemia\/Reperfusion Injury in Rats. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0146783"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ana.24655","article-title":"Targeting coagulation factor XII as a novel therapeutic option in brain trauma","volume":"79","author":"Hopp","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1160\/TH10-05-0307","article-title":"Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis","volume":"105","author":"Salomon","year":"2011","journal-title":"Thromb. Haemost."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood-2008-06-163675","article-title":"Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI","volume":"113","author":"Tucker","year":"2009","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","article-title":"Reduced incidence of ischemic stroke in patients with severe factor XI deficiency","volume":"111","author":"Salomon","year":"2008","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/hae.12402","article-title":"Rare bleeding disorders\u2014Bleeding assessment tools, laboratory aspects and phenotype and therapy of FXI deficiency","volume":"20","author":"James","year":"2014","journal-title":"Haemophilia"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"107676","DOI":"10.1016\/j.pharmthera.2020.107676","article-title":"A novel rationale for targeting FXI: Insights from the hemostatic microRNA targetome for emerging anticoagulant strategies","volume":"218","author":"Nourse","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for Prevention of Venous Thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021011725","article-title":"The contact activation inhibitor AB023 in heparin-free hemodialysis: Results of a randomized phase 2 clinical trial","volume":"138","author":"Lorentz","year":"2021","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood-2010-02-270918","article-title":"A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo","volume":"116","author":"Cheng","year":"2010","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1160\/TH13-05-0429","article-title":"Two novel inhibitory anti-human factor XI antibodies prevent cessation of blood flow in a murine venous thrombosis model","volume":"110","author":"Knaup","year":"2013","journal-title":"Thromb. Haemost."},{"key":"ref_59","first-page":"A13747","article-title":"Abstract 13747: Phase 1a\/1b Study of EP-7041: A novel, potent, selective, small molecule FXIa inhibitor","volume":"136","author":"Hayward","year":"2017","journal-title":"Circulation"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the Prevention of Venous Thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jth.15588","article-title":"Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits","volume":"20","author":"Wong","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_62","unstructured":"(2022, September 29). Bristol Myers Squibb\u2014Late-Breaking Results from Phase 2 AXIOMATIC-SSP Study of Milvexian, an Investigational OralFactor XIa Inhibitor, Show Favorable Antithrombotic Profile in Combination with Dual Antiplatelet Therap. Available online: https:\/\/news.bms.com\/news\/details\/2022\/Late-Breaking-Results-From-Phase-2-AXIOMATIC-SSP-Study-of-Milvexian-an-Investigational-Oral-Factor-XIa-Inhibitor-Show-Favorable-Antithrombotic-Profile-in-Combination-With-Dual-Antiplatelet-Therapy\/default.aspx."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): A multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes Following Acute Myocardial Infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): An international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/bcp.13520","article-title":"First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, smallmolecule factor XIa inhibitor in non-Japaneseand Japanese healthy subjects","volume":"84","author":"Perera","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1111\/bcp.14732","article-title":"ONO-7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first-in-human study","volume":"87","author":"Beale","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11239-015-1258-7","article-title":"In vitro, antithrombotic and bleeding time studies of BMS-654457, a small-molecule, reversible and direct inhibitor of factor XIa","volume":"40","author":"Wong","year":"2015","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_69","first-page":"99","article-title":"Discovery of ONO-5450598, a highly orally bioavailable small molecule factor XIa inhibitor: The pharmacokinetic and pharmacological profiles","volume":"1","author":"Kouyama","year":"2017","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11239-011-0599-0","article-title":"A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits","volume":"32","author":"Wong","year":"2011","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"Bethune","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.drudis.2014.06.028","article-title":"Factor IXa as a target for anticoagulation in thrombotic disorders and conditions","volume":"19","author":"Smiley","year":"2014","journal-title":"Drug Discov. Today"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2217\/fca.12.5","article-title":"The REG1 anticoagulation system: A novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome","volume":"8","author":"Vavalle","year":"2012","journal-title":"Future Cardiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/13543776.2022.2026926","article-title":"Factor IX(a) inhibitors: An updated patent review (2003\u2013present)","volume":"32","author":"Afosah","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/eurheartj\/ehs232","article-title":"A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: Results of the RADAR trial","volume":"34","author":"Povsic","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0140-6736(15)00515-2","article-title":"Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): A randomised clinical trial","volume":"387","author":"Lincoff","year":"2016","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/2048872617703065","article-title":"Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes","volume":"8","author":"Staudacher","year":"2019","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1067\/mcp.2002.122276","article-title":"Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans","volume":"71","author":"Chow","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1538-7836.2007.02872.x","article-title":"Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: An exploratory study","volume":"6","author":"Eriksson","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/cvr\/cvab003","article-title":"The Key Contribution of Platelet and Vascular Arachidonic Acid Metabolism to the Pathophysiology of Atherothrombosis","volume":"117","author":"Badimon","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevationThe Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)","volume":"42","author":"Collet","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_84","first-page":"998","article-title":"Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: Benefits and risks of antithrombotic therapy for cardiovascular disease prevention","volume":"14","author":"Walker","year":"2020","journal-title":"Ecancermedicalscience"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1472-8206.2011.00986.x","article-title":"Pharmacokinetic basis of the antiplatelet action of prasugrel","volume":"26","author":"Huber","year":"2012","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1161\/ATVBAHA.114.303724","article-title":"A novel \u03b1iIb\u03b23 antagonist for prehospital therapy of myocardial infarction","volume":"34","author":"Li","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijcard.2012.06.001","article-title":"Efficacy and safety of early versus late glycoprotein IIb\/IIIa inhibitors for PCI","volume":"162","author":"Xu","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"E364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/jamaneurol.2020.4396","article-title":"Ticagrelor Added to Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack in Prevention of Disabling Stroke: A Randomized Clinical Trial","volume":"78","author":"Amarenco","year":"2021","journal-title":"JAMA Neurol."},{"key":"ref_93","first-page":"666","article-title":"Cerebral infarction and transient ischemic attack","volume":"74","author":"Sahara","year":"2016","journal-title":"Nihon Rinsho"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"410","DOI":"10.21037\/atm.2019.08.08","article-title":"Targeting ticagrelor: A novel therapy for emergency reversal","volume":"7","author":"Cave","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"100733","DOI":"10.1016\/j.blre.2020.100733","article-title":"Interplay between platelets and coagulation","volume":"46","author":"Sang","year":"2021","journal-title":"Blood Rev."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/phar.2620","article-title":"Safety and efficacy of a platelet glycoprotein Ib inhibitor for patients with non-ST segment elevation myocardial infarction: A phase Ib\/IIa study","volume":"41","author":"Zheng","year":"2021","journal-title":"Pharmacotherapy"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1111\/bph.13178","article-title":"A novel snake venom-derived GPIb antagonist, anfibatide, protects mice from acute experimental ischaemic stroke and reperfusion injury","volume":"172","author":"Li","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12031-019-01402-z","article-title":"Anfibatide Preserves Blood-Brain Barrier Integrity by Inhibiting TLR4\/RhoA\/ROCK Pathway After Cerebral Ischemia\/Reperfusion Injury in Rat","volume":"70","author":"Gong","year":"2020","journal-title":"J. Mol. Neurosci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"843404","DOI":"10.3389\/fimmu.2022.843404","article-title":"Platelets, Thromboinflammation and Neurovascular Disease","volume":"13","author":"Sun","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s12265-012-9435-y","article-title":"Novel antiplatelet agents: ALX-0081, a Nanobody directed towards von Willebrand factor","volume":"6","author":"Bartunek","year":"2013","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1055\/s-0040-1713888","article-title":"von Willebrand Factor Predicts Mortality in ACS Patients Treated with Potent P2Y12 Antagonists and is Inhibited by Aptamer BT200 Ex Vivo","volume":"120","author":"Kovacevic","year":"2020","journal-title":"Thromb. Haemost."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1038\/s41598-021-82747-7","article-title":"The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients","volume":"11","author":"Kovacevic","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"9882","DOI":"10.3390\/ijms23179882","article-title":"Modulation of Glycoprotein VI and Its Downstream Signaling Pathways as an Antiplatelet Target","volume":"23","author":"Nayak","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.vph.2018.08.007","article-title":"Intracellular platelet signalling as a target for drug development","volume":"111","author":"Vilahur","year":"2018","journal-title":"Vasc. Pharmacol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"107630","DOI":"10.1016\/j.pharmthera.2020.107630","article-title":"Glycoprotein VI\u2014Novel target in antiplatelet medication","volume":"217","author":"Borst","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"100592","DOI":"10.1016\/j.blre.2019.100592","article-title":"Clinical significance of altered collagen-receptor functioning in platelets with emphasis on glycoprotein VI","volume":"38","author":"Nurden","year":"2019","journal-title":"Blood Rev."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2141.2007.06799.x","article-title":"Platelet glycoprotein VI-related clinical defects","volume":"139","author":"Arthur","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1182\/bloodadvances.2022008531","article-title":"Introduction of an ancient founder glycoprotein VI (GP6) mutation into the Chilean population","volume":"6","author":"Dalby","year":"2022","journal-title":"Blood Adv."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1365-2141.1995.tb08900.x","article-title":"Platelets with 10% of the normal amount of glycoprotein VI have an impaired response to collagen that results in a mild bleeding tendency","volume":"89","author":"Arai","year":"1995","journal-title":"Br. J. Haematol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.thromres.2005.08.001","article-title":"GPVI-deficient mice lack collagen responses and are protected against experimentally induced pulmonary thromboembolism","volume":"118","author":"Lockyer","year":"2006","journal-title":"Thromb. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/CIRCULATIONAHA.110.980623","article-title":"Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans","volume":"123","author":"Ungerer","year":"2011","journal-title":"Circulation"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/jamacardio.2021.0475","article-title":"Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial","volume":"6","author":"Mayer","year":"2021","journal-title":"JAMA Cardiol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1080\/19420862.2017.1336592","article-title":"Design, development and characterization of ACT017, a humanized Fab that blocks platelet\u2019s glycoprotein VI function without causing bleeding risks","volume":"9","author":"Lebozec","year":"2017","journal-title":"MAbs"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/jcph.1616","article-title":"Population Pharmacokinetic\/Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation","volume":"2020","author":"Renaud","year":"2020","journal-title":"Pharmacomet. J. Clin. Pharmacol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1161\/ATVBAHA.118.312314","article-title":"Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab","volume":"39","author":"Lebozec","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.3324\/haematol.2019.235549","article-title":"Novel aptamer to von Willebrand factor A1 domain (TAGX-0004) shows total inhibition of thrombus formation superior to ARC1779 and comparable to caplacizumab","volume":"105","author":"Sakai","year":"2020","journal-title":"Haematologica"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1161\/STROKEAHA.111.616649","article-title":"The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: A randomized trial","volume":"42","author":"Markus","year":"2011","journal-title":"Stroke"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Lapchak, P.A., Doyan, S., Fan, X., and Woods, C.M. (2013). Synergistic Effect of AJW200, a von Willebrand Factor Neutralizing Antibody with Low Dose (0.9 mg\/mg) Thrombolytic Therapy Following Embolic Stroke in Rabbits. J. Neurol. Neurophysiol., 4.","DOI":"10.4172\/2155-9562.1000146"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1161\/hq0102.101520","article-title":"Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys","volume":"22","author":"Kageyama","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1182\/blood.V99.10.3623","article-title":"Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons","volume":"99","author":"Wu","year":"2002","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1160\/TH08-02-0073","article-title":"The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons","volume":"100","author":"Fontayne","year":"2008","journal-title":"Thromb. Haemost."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/hyb.2009.0068","article-title":"Engineering and characterization of a chimeric anti-platelet glycoprotein Iba monoclonal antibody and preparation of its Fab fragment","volume":"29","author":"Yang","year":"2010","journal-title":"Hybridoma"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/01.ATV.0000225697.98093.ed","article-title":"Two-phase antithrombotic protection after anti-glycoprotein VI treatment in mice","volume":"26","author":"Schulte","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.193.4.459","article-title":"Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice","volume":"193","author":"Nieswandt","year":"2001","journal-title":"J. Exp. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/ATVBAHA.118.311758","article-title":"Selective Inhibition of PAR4 (Protease-Activated Receptor 4)-Mediated Platelet Activation by a Synthetic Nonanticoagulant Heparin Analog","volume":"39","author":"Lin","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.redox.2017.05.019","article-title":"HPW-RX40 prevents human platelet activation by attenuating cell surface protein disulfide isomerases","volume":"13","author":"Kung","year":"2017","journal-title":"Redox Biol."},{"key":"ref_128","unstructured":"Khodier, C., VerPlank, L., Nag, P.P., Pu, J., Wurst, J., Pilyugina, T., Dockendorff, C., Galinski, C.N., Scalise, A.A., and Passam, F. (2010). Identification of ML359 as a small molecule inhibitor of protein disulfide isomerase. Probe Reports from the NIH Molecular Libraries Program, National Center for Biotechnology Information (US)."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1161\/ATVBAHA.117.309868","article-title":"First Selective 12-LOX Inhibitor, ML355, Impairs Thrombus Formation and Vessel Occlusion In Vivo With Minimal Effects on Hemostasis","volume":"37","author":"Adili","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ejmech.2016.06.010","article-title":"Discovery and antiplatelet activity of a selective PI3K\u03b2 inhibitor (MIPS-9922)","volume":"122","author":"Zheng","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1161\/01.RES.0000232317.84122.0c","article-title":"Conformation-specific blockade of the integrin GPIIb\/IIIa: A novel antiplatelet strategy that selectively targets activated platelets","volume":"99","author":"Schwarz","year":"2006","journal-title":"Circ. Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"eaaz7287","DOI":"10.1126\/scitranslmed.aaz7287","article-title":"High-loading G\u03b1 13-binding EXE peptide nanoparticles prevent thrombosis and protect mice from cardiac ischemia\/reperfusion injury","volume":"12","author":"Pang","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1021\/jm500588w","article-title":"N-[6-(4-butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H -indole-3-carboxamide (SAR216471), a novel intravenous and oral, reversible, and directly acting P2Y12 antagonist","volume":"57","author":"Boldron","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1021\/acs.jmedchem.8b01971","article-title":"Optimization of P2Y 12 Antagonist Ethyl 6-(4-((Benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) Led to the Discovery of an Oral Antiplatelet Agent with Improved Druglike Properties","volume":"62","author":"Kong","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"6150","DOI":"10.1021\/jm5006226","article-title":"Discovery of 4-aryl-7-hydroxyindoline based P2Y1 antagonists as novel antiplatelet agents","volume":"57","author":"Yang","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s11239-015-1302-7","article-title":"The P2Y1 receptor antagonist MRS2500 prevents carotid artery thrombosis in cynomolgus monkeys","volume":"41","author":"Wong","year":"2016","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1161\/ATVBAHA.115.306885","article-title":"Synergistic inhibition of both P2Y1 and P2Y12 adenosine diphosphate receptors as novel approach to rapidly attenuate platelet-mediated thrombosis","volume":"36","author":"Gremmel","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1161\/ATVBAHA.116.308604","article-title":"Trowaglerix Venom Polypeptides as a Novel Antithrombotic Agent by Targeting Immunoglobulin-Like Domains of Glycoprotein VI in Platelet","volume":"37","author":"Chang","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1161\/ATVBAHA.115.306883","article-title":"The Novel Oral Syk Inhibitor, Bl1002494, Protects Mice from Arterial Thrombosis and Thromboinflammatory Brain Infarction","volume":"36","author":"Stegner","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3389\/fcvm.2018.00142","article-title":"Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients","volume":"5","author":"Tullemans","year":"2018","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"C373","DOI":"10.1152\/ajpcell.00325.2015","article-title":"Oral administration of Bruton\u2019s tyrosine kinase inhibitors impairs GPVI-mediated platelet function","volume":"310","author":"Rigg","year":"2016","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Perrella, G., Montague, S.J., Brown, H.C., Garcia Quintanilla, L., Slater, A., Stegner, D., Thomas, M., Heemskerk, J.W.M., and Watson, S.P. (2022). Role of Tyrosine Kinase Syk in Thrombus Stabilisation at High Shear. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010493"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/09537104.2020.1849600","article-title":"Novel antiplatelet strategies targeting GPVI, CLEC-2 and tyrosine kinases","volume":"32","author":"Harbi","year":"2021","journal-title":"Platelets"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3324\/haematol.2019.218545","article-title":"Low-dose Btk inhibitors selectively block platelet activation by CLEC-2","volume":"106","author":"Nicolson","year":"2021","journal-title":"Haematologica"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.thromres.2011.11.001","article-title":"Mechanisms of platelet activation by thrombin: A short history","volume":"129","year":"2012","journal-title":"Thromb. Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1161\/CIRCULATIONAHA.114.015042","article-title":"Efficacy and Safety of Vorapaxar with and without a Thienopyridine for Secondary Prevention in Patients with Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2\u00b0P-TIMI 50","volume":"132","author":"Bohula","year":"2015","journal-title":"Circulation"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ahj.2014.06.017","article-title":"Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: Insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)","volume":"168","author":"Jones","year":"2014","journal-title":"Am. Heart J."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/2048872616644910","article-title":"Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2\u00b0P-TIMI 50 trial","volume":"6","author":"Kosova","year":"2017","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.114.013774","article-title":"Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: Findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial","volume":"131","author":"Cavender","year":"2015","journal-title":"Circulation"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e015865","DOI":"10.1161\/JAHA.120.015865","article-title":"Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated with Potent Oral P2Y 12 Receptor Inhibitors with and Without Aspirin: Results of the VORA-PRATIC Study","volume":"9","author":"Franchi","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1161\/ATVBAHA.115.306777","article-title":"Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects with Coronary Artery Disease","volume":"36","author":"Gurbel","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1161\/ATVBAHA.120.315168","article-title":"PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study","volume":"40","author":"Kuliopulos","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1161\/ATVBAHA.120.314960","article-title":"Antithrombotic Effects of Combined PAR (Protease-Activated Receptor)-4 Antagonism and Factor Xa Inhibition","volume":"40","author":"Meah","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1080\/09537104.2022.2088719","article-title":"New oral protease-activated receptor 4 antagonist BMS-986120: Tolerability, pharmacokinetics, pharmacodynamics, and gene variant effects in humans","volume":"33","author":"Merali","year":"2022","journal-title":"Platelets"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"eaaf5294","DOI":"10.1126\/scitranslmed.aaf5294","article-title":"Blockade of protease-activated receptor- 4(PAR4) provides robust antithrombotic activity with low bleeding","volume":"9","author":"Wong","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/ATVBAHA.117.310104","article-title":"PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation","volume":"38","author":"Wilson","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1111\/j.1538-7836.2012.04898.x","article-title":"Human target validation of phosphoinositide 3-kinase (PI3K)\u03b2: Effects on platelets and insulin sensitivity, using AZD6482 a novel PI3K\u03b2 inhibitor","volume":"10","author":"Nylander","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/jth.13027","article-title":"Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase \u03b2 inhibition and aspirin in man","volume":"13","author":"Nylander","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/13543784.2020.1764533","article-title":"Selatogrel, a novel P2Y 12 inhibitor: A review of the pharmacology and clinical development","volume":"29","author":"Milluzzo","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.thromres.2021.01.026","article-title":"Selatogrel, a reversible P2Y12 receptor antagonist, has reduced off-target interference with haemostatic factors in a mouse thrombosis model","volume":"200","author":"Crescence","year":"2021","journal-title":"Thromb. Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1182\/blood-2004-02-0534","article-title":"Reciprocal cross-talk between P2Y1 and P2Y12 receptors at the level of calcium signaling in human platelets","volume":"104","author":"Hardy","year":"2004","journal-title":"Blood"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/1074248419899314","article-title":"Novel Antiplatelet Agents in Cardiovascular Disease","volume":"25","author":"Tscharre","year":"2020","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e016552","DOI":"10.1161\/JAHA.120.016552","article-title":"First Human Use of RUC-4: A Nonactivating Second-Generation Small-Molecule Platelet Glycoprotein IIb\/IIIa (Integrin \u03b1IIb\u03b23) Inhibitor Designed for Subcutaneous Point-of-Care Treatment of ST-Segment-Elevation Myocardial Infarction","volume":"9","author":"Kereiakes","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"401","DOI":"10.4244\/EIJ-D-21-00287","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of subcutaneous administration of a novel glycoprotein IIb\/IIIa inhibitor, RUC-4, in patients with ST-segment elevation myocardial infarction","volume":"17","author":"Bor","year":"2021","journal-title":"EuroIntervention"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1182\/blood-2013-03-492504","article-title":"Platelet protein disulfide isomerase is required for thrombus formation but not for hemostasis in mice","volume":"122","author":"Kim","year":"2013","journal-title":"Blood"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/ATVBAHA.114.303410","article-title":"Therapeutic implications of protein disulfide isomerase inhibition in thrombotic disease","volume":"35","author":"Flaumenhaft","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/09537104.2020.1763731","article-title":"Novel antiplatelet targets in the treatment of acute coronary syndromes","volume":"32","author":"Alenazy","year":"2021","journal-title":"Platelets"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"e125851","DOI":"10.1172\/jci.insight.125851","article-title":"Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer","volume":"4","author":"Zwicker","year":"2019","journal-title":"JCI Insight"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e89373","DOI":"10.1172\/jci.insight.89373","article-title":"Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation","volume":"2","author":"Stopa","year":"2017","journal-title":"JCI Insight"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.1055\/s-0039-1694028","article-title":"The Metabolites of the Dietary Flavonoid Quercetin Possess Potent Antithrombotic Activity, and Interact with Aspirin to Enhance Antiplatelet Effects","volume":"3","author":"Stainer","year":"2019","journal-title":"TH Open"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1538-7836.2007.02483.x","article-title":"Plaque progression and regression in atherothrombosis","volume":"5","author":"Ibanez","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/eurheartj\/ehx181","article-title":"Position paper of the European Society of Cardiology-working group of coronary pathophysiology and microcirculation: Obesity and heart disease","volume":"38","author":"Badimon","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2174\/156652406778018590","article-title":"The role of high-density lipoprotein cholesterol in the prevention and possible treatment of cardiovascular diseases","volume":"6","author":"Choi","year":"2006","journal-title":"Curr. Mol. Med."}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/9\/11\/397\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:19:46Z","timestamp":1760145586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/9\/11\/397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":173,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["jcdd9110397"],"URL":"https:\/\/doi.org\/10.3390\/jcdd9110397","relation":{},"ISSN":["2308-3425"],"issn-type":[{"value":"2308-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,16]]}}}